Recent Company News

• 09:17 AM ET Dec 15, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 09:01 AM ET Dec 15, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 08:21 AM ET Dec 15, 2025
  

  StreetAccount Summary - US Pre-market trading

• 05:44 PM ET Dec 14, 2025
  

  Radiopharm Theranostics achieves primary endpoint in 92% of patients at interim analysis of RAD 101 Phase 2B imaging trial in Brain Metastases ($4.26, 0.00)

• 12:44 AM ET Dec 03, 2025
  

  Radiopharm Theranostics completes SPP, raises A$0.4M priced at A$0.03/sh (A$0.02, 0.00)

• 04:37 PM ET Nov 17, 2025
  

  Radiopharm Theranostics receives approval to initiate the Phase 1 therapeutic trial of RAD 402 (KLK3-mAb with Tb161) in advanced prostate cancer ($4.52, 0.00)

• 04:33 PM ET Nov 16, 2025
  

  Radiopharm Theranostics enrolls 50% of patients in Phase 2b study of RAD101 ($4.40, 0.00)

• 06:49 PM ET Nov 11, 2025
  

  Radiopharm Theranostics completes enrollment of 2nd cohort of patients in Phase 1 study of 177Lu-RAD204; starts enrollment of 3rd cohort ($4.59, 0.00)

• 01:17 PM ET Nov 04, 2025
  

  Transcript Intelligence: Radiopharm Theranostics at Deutsche Bank Depositary Receipts Virtual Investor Conference ($4.84, -0.04)

• 11:36 PM ET Oct 27, 2025
  

  Radiopharm Theranostics reports Q1 net cash from / (used in) operating activities (A$9.3M) - Appendix 4C ($5.28, 0.00)